摘要
There are three clinically used sources of hematopoietic stem cells(HSC)and hematopoietic progenitor cells(HPC)for hematopoietic cell transplantation(HCT):bone marrow(BM),umbilical cord blood(CB),and cytokine-induced mobilized peripheral blood(mPB)cells.1–5 Each source of clinically used cells has its advantages and disadvantages.Of these,mPB cells make up the majority of autologous and allogeneic HCT efforts worldwide.The advantage of mPB is that one can,in many cases,usually collect more than enough cells to ensure a rapid and longlasting donor graft,be it for autologous or allogeneic HCT.The“gold”standard for collection of mPB has been,and continues to be,the cells mobilized from the BM to peripheral blood by multiple additions of the cytokine granulocyte colony-stimulating factor(G-CSF)each day over a number of days.However,GCSF-induced mPB does not always yield enough cells for a graft,takes 4–5 days for optimal yield of HSC and HPC,and can entail leukocytapheresis efforts to obtain enough cells for a transplant.This requires the donor to be ready and willing for multiple days of G-CSF treatment.Moreover,there are patients who do not mobilize HSC and HPC well for a number of reasons,including low numbers of these cells inherent in the BM of the patient undergoing an autologous transplant—an example being patients with Fanconi anemia,under such conditions,one might attempt to use gene therapy on the mobilized cells to correct the Fanconi anemia gene defect.New,simple,and less timeconsuming efforts to mobilize HSC and HPC for clinical use would be advantageous.In this context,a recent article by Hoggatt et al.6 describes a new regimen combining two small molecules(GRO-beta and AMD3100)to quickly mobilize HSC and HPC in mice.
